Benchmark Holdings PLC BMK08+CleanTreat Update (7421V)
April 16 2021 - 5:00AM
UK Regulatory
TIDMBMK
RNS Number : 7421V
Benchmark Holdings PLC
16 April 2021
16 April 2021
Benchmark Holdings
("Benchmark" or the "Company")
BMK08+CleanTreat Ò Update
Ratification of Maximum Residue Limit under European Law
Significant milestone towards the commercialisation of BMK08 and
CleanTreat Ò
Further to the notification made on 10 September 2020, Benchmark
Holdings is pleased to announce that the MRL (Maximum Residue
Limit) for its novel sea lice treatment BMK08 has now been ratified
under European Law. The MRL confirms the safety of Benchmark's sea
lice solution for consumers and represents a significant milestone
in the regulatory approval process towards the anticipated
commercial launch of BMK08 and CleanTreat Ò in Norway. The
commercial launch remains subject to the grant of a Marketing
Authorisation in Norway.
BMK08 and CleanTreat Ò is a transformational solution addressing
the biggest biological challenge in salmon farming. The MRL EU
ratification is the culmination of almost a decade of research and
development, a rigorous trial programme and substantial capital
investment by Benchmark.
Trond Williksen, CEO, commented:
"The ratification of the MRL is a further stepping stone towards
commercialisation following the announcement of our first customer
agreements for CleanTreat â announced in March.
Sea lice continues to be the biggest biological challenge for
salmon producers and Benchmark's novel solution addresses this
challenge in a sustainable way both in terms of animal welfare and
environmental impact."
Enquiries:
Benchmark Holdings plc Tel: 020 3696 0630
Ivonne Cantu, Investor Relations Director
Rachel Aninakwah, Communications
Numis (Broker and NOMAD) Tel: 020 7260 1000
James Black / Freddie Barnfield / Duncan
Monteith
M HP
Katie Hunt /Alistair de Kare-Silver Tel: 020 3128 8742
benchmark@mhpc.com
About Benchmark
Benchmark's mission is to enable aquaculture producers to
improve their sustainability and profitability.
We bring together biology and technology, to develop innovative
products which improve yield, quality and animal health and welfare
for our customers. We do this by improving the genetic make-up,
health and nutrition of their stock - from broodstock and hatchery
through to nursery and grow out.
Benchmark has a broad portfolio of products and solutions,
including salmon eggs, live feed (Artemia), diets and probiotics
and sea lice treatments. Find out more at www.benchmarkplc.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDDKABNCBKKAQD
(END) Dow Jones Newswires
April 16, 2021 06:00 ET (10:00 GMT)
Benchmark (LSE:BMK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Benchmark (LSE:BMK)
Historical Stock Chart
From Apr 2023 to Apr 2024